Copper and Cu NanoParticles / Proteasome Cancer Research Results

Cu, Copper and Cu NanoParticles: Click to Expand ⟱
Features:
Copper
Metal
Copper levels are considerably elevated in various malignancies.
Copper [Cu(II)] is a transition and trace element in living organisms. It increases reactive oxygen species (ROS) and free-radical generation that might damage biomolecules like DNA, proteins, and lipids.
RDA: 900 mcg, ULs: 10,000mcg

Copper (dietary/physiology) ≠ copper-loading therapeutics ≠ copper nanoparticles.
For Cu nanoparticles, the dominant and most reproducible theme is toxicity via ROS → mitochondrial damage/genotoxicity, not clean tumor selectivity.
- Copper acts as a critical cofactor for numerous enzymes involved in redox reactions, energy production, and connective tissue formation.
- Increased copper levels in the tumor microenvironment can enhance angiogenic signaling and thus supply the tumor with necessary oxygen and nutrients, facilitating tumor growth and metastasis.
- Copper can participate in redox cycling reactions, similar to the Fenton reaction, leading to the production of reactive oxygen species (ROS).
- Cancer cells often exhibit altered copper homeostasis, with some studies showing elevated copper levels in tumor tissues relative to normal tissues.

Copper serves a dual role in cancer: Imbalanced copper metabolism promotes tumor cell proliferation and survival by activating the receptor tyrosine kinase, PI3K/Akt/mTOR, and MAPK/ERK signaling pathways, while cuproptosis suppresses tumor growth by inducing cell death and activating immune responses

Two main approaches are:
- Copper Chelation: Drugs that bind copper (chelators) can reduce the bioavailability of copper, potentially inhibiting angiogenesis and other copper-dependent tumor processes.
- Copper Ionophores: These agents facilitate the transport of copper into cancer cells to induce cytotoxicity by elevating intracellular copper levels beyond a tolerable threshold, leading to cell death.

- Depletion of glutathione and stimulation of lipid peroxidation, catalase and superoxide dismutase.
- Studies have shown that the level of copper in tumour cells and blood serum from cancer patients is elevated, and the conclusion is that cancer cells need more copper than healthy cells. (but also sometimes depleted).
- Copper is a double-edged sword, maintaining normal cell development and promoting tumor development.
- Tumor tissue has a higher demand for copper and is more susceptible to copper homeostasis, copper may modulate cancer cell survival through reactive oxygen species (ROS) excessive accumulation, proteasome inhibition and anti-angiogenesis.

Copper and Cu NanoParticles — Copper is an essential redox-active trace metal and transition element that becomes oncology-relevant through copper homeostasis, copper-dependent enzymes, copper chelation, copper ionophore/copper-loading strategies, and copper-based nanoparticles. The formal classification is mixed: elemental/ionic metal biology, copper coordination chemistry, micronutrient/mineral exposure, and inorganic/nano-oncology modality. Standard abbreviations include Cu, Cu(I), Cu(II), CuNP, CuO-NP, Cu2O-NP, DSF/Cu, and TM for tetrathiomolybdate. The most important distinction is that dietary copper physiology, therapeutic copper depletion, copper ionophore loading, copper complexes, and copper nanoparticles are not interchangeable exposures.

Primary mechanisms (ranked):

  1. Copper homeostasis disruption and cuproptosis: intracellular Cu accumulation can bind lipoylated mitochondrial TCA-cycle proteins, promote protein aggregation, reduce Fe-S protein integrity, and trigger proteotoxic mitochondrial cell death.
  2. Copper-dependent tumor biology: copper availability supports angiogenesis, ECM remodeling, invasion/metastasis programs, and copper-requiring enzymes such as LOX/LOXL and SOD1.
  3. CuNP and CuO-NP oxidative cytotoxicity: particle dissolution/surface chemistry and released Cu ions can increase ROS, mitochondrial injury, DNA damage, apoptosis, inflammation, and lipid peroxidation.
  4. Copper chelation: copper depletion can suppress angiogenesis and tumor microenvironment support, but excessive depletion creates systemic deficiency risk.
  5. Copper ionophore or copper-loading strategies: agents such as disulfiram/copper can increase intracellular copper stress and sensitize some models, but clinical results are inconsistent and toxicity can increase.
  6. Redox and GSH axis: copper can amplify oxidative stress and deplete thiol buffering; this is mechanistically central for CuNP/CuO-NP toxicity and context-dependent for copper complexes or ionophores.
  7. Radiosensitization or chemosensitization: reported mainly in preclinical or early clinical DSF/Cu and copper-complex contexts, not established as a standard oncology treatment.

Bioavailability / PK relevance: Oral nutritional copper is normally tightly regulated by absorption, biliary excretion, ceruloplasmin binding, and intracellular chaperones. Copper nanoparticles and copper oxide nanoparticles have distinct PK and toxicology constraints because particle size, coating, dissolution, route of exposure, aggregation, and organ deposition can dominate exposure. Copper chelation requires systemic copper lowering, while copper-loading strategies require sufficient intracellular Cu delivery without unacceptable normal-tissue toxicity.

In-vitro vs systemic exposure relevance: Many CuNP/CuO-NP anticancer experiments use direct cell-culture concentrations that may exceed safe or achievable systemic exposure and may reflect non-selective cytotoxicity. For ionic copper, free copper concentrations in vivo are extremely buffered, so simple CuSO4 or CuCl2 in-vitro experiments do not map cleanly onto physiological free copper. For DSF/Cu and copper complexes, exposure relevance depends on complex formation, albumin/protein binding, tumor delivery, and copper transporter state.

Clinical evidence status: Copper biology is strongly supported mechanistically. Copper chelation has small human and phase II evidence, mainly as an anti-angiogenic or microenvironment strategy, but is not established standard oncology care. DSF/Cu has phase I/II and randomized clinical evidence in glioblastoma; the recurrent glioblastoma randomized trial did not show survival benefit and reported increased toxicity. CuNP/CuO-NP anticancer claims remain predominantly preclinical, with major translation constraints from oxidative, hepatic, renal, inflammatory, genotoxic, and mitochondrial toxicity signals.

Interpretation note: Copper biology and copper nanoparticles should not be treated as equivalent exposures. Ionic copper, nutritional copper, copper chelation, copper ionophores, copper complexes, CuNPs, CuO-NPs, and Cu2O-NPs differ in pharmacokinetics, intracellular copper delivery, redox behavior, biodistribution, and toxicity. Directional tags such as ROS↑, angiogenesis↑/↓, GSH↓, NRF2↑/↓, and chemosensitization should be interpreted according to exposure class.

Copper Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Copper homeostasis and cuproptosis Intracellular Cu ↑; lipoylated TCA protein aggregation ↑; Fe-S proteins ↓; proteotoxic stress ↑; cuproptosis ↑ Normally buffered by CTR1, ATP7A/ATP7B, metallothioneins, chaperones, ceruloplasmin, and biliary excretion R, G Mitochondrial regulated cell death Core mechanism for copper-loading strategies and copper ionophores. Most relevant in tumors with high mitochondrial respiration and vulnerable copper handling.
2 Copper-dependent angiogenesis Angiogenic tone ↑; VEGF/HIF-1α-linked signaling ↑ (context-dependent); endothelial recruitment ↑ Physiologic angiogenesis and wound repair require copper-dependent processes G Tumor vascular support Supports copper chelation as an antiangiogenic strategy. Copper sufficiency and copper depletion should be tagged separately.
3 LOX and ECM remodeling LOX/LOXL activity ↑; collagen crosslinking ↑; invasion/metastatic niche support ↑ Connective-tissue maturation and repair require copper-dependent lysyl oxidase activity G Invasion and metastasis support Mechanistically important for stromal remodeling and metastasis rather than acute cancer-cell killing.
4 Copper chelation Available copper ↓; angiogenesis ↓; SOD1/LOX-dependent support ↓; metastatic niche support ↓ (context-dependent) Copper-dependent enzymes ↓ if depletion is excessive; deficiency risk ↑ G Microenvironment suppression Best represented as a separate therapeutic direction from copper supplementation or copper ionophore loading.
5 Disulfiram and copper ionophore stress Intracellular copper stress ↑; ROS ↑; proteasome stress ↑; ALDH/resistance pathways ↓ (model-dependent); apoptosis ↑ Toxicity ↑ possible; hepatic, neurologic, and drug-alcohol constraints are relevant R, G Experimental copper-loading therapy Preclinical signal is strong, but clinical results are mixed. Should not be generalized to dietary copper.
6 Mitochondrial ROS increase ROS ↑; mtROS ↑; mitochondrial membrane potential ↓; apoptosis ↑ Oxidative injury ↑ if copper buffering is exceeded P, R, G Redox-mediated cytotoxicity Most relevant for copper complexes, copper ionophores, and excess intracellular copper. Free Cu is highly buffered in vivo.
7 GSH and thiol redox buffering GSH ↓; GSH/GSSG ↓; oxidative vulnerability ↑; ferroptosis-like stress ↑ (context-dependent) GSH depletion can increase normal-tissue injury R, G Redox-buffer collapse Important for copper-loading and copper-complex strategies. Less applicable to normal dietary copper exposure.
8 NRF2 antioxidant response NRF2 ↓ in some copper-stress or DSF/Cu models; NRF2 ↑ as adaptive resistance in others NRF2 ↑ may protect against copper-associated oxidative stress R, G Adaptive stress response Direction is context-dependent. Use caution when assigning a single NRF2 direction to copper broadly.
9 SOD1 and copper-dependent enzymes SOD1 activity altered; copper-dependent redox enzyme support ↑ or ↓ depending on copper loading versus chelation Normal antioxidant defense, iron handling, connective tissue biology, and neurobiology depend on copper enzymes R, G Enzyme cofactor modulation Therapeutic leverage exists, but copper enzyme disruption has a narrow safety window.
10 Radiosensitization and chemosensitization ROS ↑; DNA damage ↑; TMZ/radiation response ↑ in selected models; apoptosis ↑ Normal-tissue sensitization risk ↑ if delivery is not tumor-selective R, G Adjunct sensitization Most relevant to DSF/Cu and copper complexes. Not established as a broad copper effect.
11 Clinical Translation Constraint Tumor response depends on copper transporter state, mitochondrial metabolism, GSH/NRF2 buffering, and copper-complex delivery Systemic copper is essential; excess copper and copper depletion can both cause toxicity G Exposure and safety constraint Dietary copper, copper salts, copper chelation, copper complexes, and DSF/Cu should be interpreted separately.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid redox interactions)
  • R: 30 min–3 hr (acute mitochondrial/proteotoxic stress signaling)
  • G: >3 hr (gene-regulatory adaptation and phenotype outcomes)

Copper Nanoparticles: CuNP / CuO-NP (tox + “anticancer” claims are mostly preclinical)

Copper Nanoparticle Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Nanoparticle uptake and intracellular copper release CuNP/CuO-NP uptake ↑; lysosomal dissolution ↑; intracellular Cu ions ↑; cytotoxic stress ↑ Particle uptake can also occur in normal cells; macrophage, liver, kidney, lung, and endothelial exposure are major concerns R, G Particle-driven copper stress Core CuNP mechanism. Effects depend strongly on particle size, coating, oxidation state, dissolution rate, aggregation, and route of exposure.
2 Mitochondrial ROS increase ROS ↑; mtROS ↑; mitochondrial membrane potential ↓; ATP ↓; apoptosis ↑ Oxidative injury ↑; mitochondrial toxicity ↑ when exposure exceeds antioxidant capacity P, R, G Oxidative cytotoxicity Central anticancer mechanism but also the main normal-tissue toxicity concern. Tumor selectivity is not automatic.
3 GSH depletion and thiol-buffer collapse GSH ↓; GSH/GSSG ↓; lipid peroxidation ↑; oxidative vulnerability ↑ GSH depletion ↑; hepatic, renal, immune-cell, and pulmonary toxicity risk ↑ R, G Redox-buffer collapse Mechanistically important for CuO-NP and CuNP toxicity. Should be tagged as dose- and exposure-dependent.
4 DNA damage and genotoxicity Oxidative DNA damage ↑; strand breaks ↑; cell-cycle arrest ↑; apoptosis ↑ Genotoxicity risk ↑ in normal cells at toxic nanoparticle exposures R, G Genome damage Common downstream result of ROS and copper-ion release. Important safety flag.
5 Apoptosis and mitochondrial death signaling BAX/caspase signaling ↑; BCL-2 ↓; cytochrome-c release ↑; apoptosis ↑ Apoptosis ↑ possible in normal exposed tissues R, G Programmed cell death Frequently reported in cell studies, but not unique to cancer cells unless targeting or differential uptake is demonstrated.
6 Inflammatory signaling and NF-κB NF-κB and inflammatory mediators ↑ or ↓ depending on model and dose Inflammation ↑; cytokine release ↑; innate immune activation ↑ R, G Inflammatory stress For CuNPs, NF-κB activation often indicates toxic inflammatory response rather than selective anticancer benefit.
7 NRF2 antioxidant response NRF2/HO-1 ↑ as adaptive defense; NRF2 collapse or ↓ may occur at high toxic exposure NRF2 ↑ may be protective against oxidative nanoparticle injury R, G Stress adaptation Usually secondary to ROS. Direction depends on exposure severity and time point.
8 Lipid peroxidation and ferroptosis-like stress Lipid ROS ↑; membrane damage ↑; ferroptosis-like death ↑ (model-dependent) Lipid peroxidation ↑; membrane injury ↑ R, G Oxidative membrane injury Can overlap with ferroptosis biology but should not be called ferroptosis unless GPX4, iron dependence, lipid peroxide rescue, or ferroptosis inhibitors are tested.
9 Ca²⁺ and membrane injury Membrane damage ↑; intracellular Ca²⁺ dysregulation ↑; mitochondrial permeability stress ↑ Ca²⁺ dysregulation and membrane toxicity ↑ possible in normal cells P, R Membrane and mitochondrial destabilization Relevant when CuNP/CuO-NP exposure causes membrane disruption or mitochondrial permeability transition.
10 Angiogenesis modulation Angiogenesis ↓ in some CuNP/CuO-NP anticancer models through oxidative or endothelial toxicity; angiogenic copper biology may also be supported by released copper Endothelial toxicity ↑; wound repair interference ↑ possible G Vascular modulation Direction is formulation- and dose-dependent. Do not merge with dietary copper angiogenesis support.
11 Radiosensitization and chemosensitization ROS ↑; DNA damage ↑; chemo/radiation response ↑ in selected preclinical models Normal-tissue sensitization risk ↑ without tumor-selective delivery R, G Adjunct sensitization Preclinical concept. Requires targeting, biodistribution, and toxicity validation before clinical interpretation.
12 Clinical Translation Constraint Anticancer effects depend on tumor uptake, particle dissolution, coating, size, aggregation, and local Cu release Systemic toxicity, immune activation, liver/kidney deposition, genotoxicity, and poor tumor selectivity are major constraints G Nanomedicine delivery constraint Most CuNP/CuO-NP oncology evidence remains preclinical. Direct in-vitro cytotoxicity should be weighted lower than in-vivo targeted-delivery evidence.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid ROS/redox interactions at particle surfaces)
  • R: 30 min–3 hr (mitochondrial stress + inflammatory signaling)
  • G: >3 hr (genotoxicity, apoptosis, organ-level outcomes)
Proteasome, Proteasome: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
The proteasome is a crucial component of the cellular machinery responsible for degrading ubiquitinated proteins, which are proteins tagged for destruction. This process is essential for maintaining cellular homeostasis, regulating the cell cycle, and controlling various signaling pathways.
Many cancer cells exhibit increased expression of proteasome subunits. This upregulation can enhance the proteasome's capacity to degrade proteins, including those that regulate cell cycle progression and apoptosis, thereby promoting tumor growth and survival.

Proteasome inhibitors act by blocking the activity of the proteasome, a crucial cellular complex responsible for degrading most intracellular proteins.
-The proteasome is responsible for degrading ubiquitin-tagged proteins, including misfolded, damaged, or regulatory proteins. By inhibiting the proteasome’s function, these proteins accumulate within the cell.
-Accumulated proteins can lead to increased cellular stress, particularly in the endoplasmic reticulum (ER) where misfolded proteins build up. This stress can trigger the unfolded protein response (UPR), which, if unresolved, may lead to apoptosis (programmed cell death).
-It is well known that ROS plays an important role in proteasome inhibition-induced cell death.

Inhibitor Drugs: bortezomib (Velcade) and carfilzomib

Natural Product Inhibitors:
-Gambogic Acid:
-Lactacystin: Origin: Isolated from the bacterium Streptomyces lactacystinaeus.
-Epoxomicin is a highly selective and potent inhibitor of the proteasome. Its structure has informed the design of synthetic drugs such as carfilzomib.
-Syringolin A
-Tyropeptins
-EGCG
-Withania somnifera (commonly known as Ashwagandha).
-Celastrol
Origin: Derived from plants of the Tripterygium genus (commonly known as Thunder God Vine).
Scientific Papers found: Click to Expand⟱
5012- DSF,  Cu,    Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems
ROS↑, ALDH↓, TumCP↓, CSCs↓, angioG↓, TumMeta↓, DNAdam↑, Proteasome↓, SOD1↓, GSR↓, ox-GSSG↑, GSH/GSSG↓, MMP↓, Akt↓, cycD1/CCND1↓, NF-kB↓, CSCs↓, MAPK↓, angioG↓, DrugR↓, EMT↓, Vim↓, BioAv↑, eff↑,
4915- DSF,  Cu,    Disulfiram: A novel repurposed drug for cancer therapy
- Review, Var, NA
ROS↑, TumCD↑, NF-kB↓, CSCs↓, ChemoSen↑, RadioS↑, eff↑, selectivity↑, Proteasome?,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH/GSSG↓, 1,   GSR↓, 1,   ox-GSSG↑, 1,   ROS↑, 2,   SOD1↓, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Cell Death ⓘ

Akt↓, 1,   MAPK↓, 1,   Proteasome?, 1,   Proteasome↓, 1,   TumCD↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 1,   CSCs↓, 3,   EMT↓, 1,  

Migration ⓘ

TumCP↓, 1,   TumMeta↓, 1,   Vim↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   ChemoSen↑, 1,   DrugR↓, 1,   eff↑, 2,   RadioS↑, 1,   selectivity↑, 1,  
Total Targets: 27

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Proteasome, Proteasome
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:64  Target#:262  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page